Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of HBW-012462 in KRAS-mutant advanced or metastatic lung cancer and other solid tumors
CTR20263058Phase 2Active
- Sponsor
- Hyperway Pharmaceutical
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HBW-012462 in bronchial carcinoma, Nonhematologic neoplasms, sponsored by Hyperway Pharmaceutical. Started Aug 2026; status: active.
02
Drugs
HBW-012462
03
Conditions
bronchial carcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20263058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263058.